DK0663905T3 - Ny fremgangsmåde dtil forestring af baccatin III og 10-desacetylbaccatin III - Google Patents

Ny fremgangsmåde dtil forestring af baccatin III og 10-desacetylbaccatin III

Info

Publication number
DK0663905T3
DK0663905T3 DK93921980.4T DK93921980T DK0663905T3 DK 0663905 T3 DK0663905 T3 DK 0663905T3 DK 93921980 T DK93921980 T DK 93921980T DK 0663905 T3 DK0663905 T3 DK 0663905T3
Authority
DK
Denmark
Prior art keywords
iii
radical
pct
formula
image
Prior art date
Application number
DK93921980.4T
Other languages
English (en)
Inventor
Jean-Manuel Mas
Jean-Noel Denis
Andrew Greene
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of DK0663905T3 publication Critical patent/DK0663905T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK93921980.4T 1992-10-05 1993-10-04 Ny fremgangsmåde dtil forestring af baccatin III og 10-desacetylbaccatin III DK0663905T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9211739A FR2696464B1 (fr) 1992-10-05 1992-10-05 Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.

Publications (1)

Publication Number Publication Date
DK0663905T3 true DK0663905T3 (da) 1997-02-03

Family

ID=9434116

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93921980.4T DK0663905T3 (da) 1992-10-05 1993-10-04 Ny fremgangsmåde dtil forestring af baccatin III og 10-desacetylbaccatin III

Country Status (24)

Country Link
US (2) US5717103A (da)
EP (1) EP0663905B1 (da)
JP (1) JP3064419B2 (da)
KR (1) KR100290663B1 (da)
AT (1) ATE147734T1 (da)
AU (1) AU689446B2 (da)
CA (1) CA2146372C (da)
CZ (1) CZ284818B6 (da)
DE (1) DE69307526T2 (da)
DK (1) DK0663905T3 (da)
ES (1) ES2096328T3 (da)
FI (1) FI115909B (da)
FR (1) FR2696464B1 (da)
GR (1) GR3022286T3 (da)
HU (1) HU225973B1 (da)
MX (1) MX9305764A (da)
NO (1) NO313141B1 (da)
NZ (1) NZ256443A (da)
PL (1) PL178090B1 (da)
RU (1) RU2123493C1 (da)
SK (1) SK281035B6 (da)
TW (1) TW372234B (da)
WO (1) WO1994007876A1 (da)
ZA (1) ZA937316B (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
MX9307777A (es) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
PT982302E (pt) * 1993-06-11 2004-07-30 Upjohn Co Utilizacao de delta 6,7-taxois antineoplasicos e composicoes farmaceuticas que os contem
KR101222904B1 (ko) 1993-07-19 2013-01-17 안지오테크 파마슈티칼즈, 인코포레이티드 항맥관형성 조성물, 당해 조성물로 피복된 스텐트 및 당해 스텐트의 제조방법
CA2172809A1 (en) * 1993-11-12 1995-05-18 Richard A. Nugent Pyrimidine-thioalkyl and alkylether compounds
IL127597A (en) * 1994-01-28 2003-07-31 Upjohn Co Iso-taxol analogs
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
EP0912504B1 (en) * 1996-05-08 2002-09-11 PHARMACIA & UPJOHN COMPANY Oxazolidine ester
US6150537A (en) * 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
US20040234472A1 (en) 2001-04-20 2004-11-25 Jackson John K. Micellar drug delivery systems for hydrophobic drugs
JP4502338B2 (ja) * 1999-09-17 2010-07-14 株式会社横浜国際バイオ研究所 タキソイド化合物の製造法
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
WO2002024179A2 (en) 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
EP2380606B1 (en) 2006-06-30 2018-03-21 Cook Medical Technologies LLC Methods of manufacturing and modifying taxane coatings for implantable medical devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
DK2300489T3 (da) 2008-06-06 2016-02-15 Neurmedix Inc Fremgangsmåder til fremstilling af 17-alkynyl-7-hydroxy-steroider og relaterede forbindelser
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP3881868B1 (en) 2013-02-15 2023-09-27 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス, インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
JP6615769B2 (ja) 2014-02-19 2019-12-04 アルデア ファーマシューティカルズ インコーポレイテッド ミトコンドリアアルデヒドデヒドロゲナーゼ2(aldh2)に結合する多環式アミド
JP6083815B2 (ja) * 2014-03-07 2017-02-22 立川ブラインド工業株式会社 タッセル
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
EP4019007A1 (en) 2016-06-01 2022-06-29 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN110267650A (zh) 2017-01-05 2019-09-20 杏国新药股份有限公司 胰脏癌治疗
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
JP2022520220A (ja) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
EP4073088A1 (en) 2019-12-12 2022-10-19 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
EP4097134A1 (en) 2020-01-29 2022-12-07 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3182472A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
CN116133671A (zh) 2020-07-14 2023-05-16 辉瑞公司 重组牛痘病毒
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
US20240010747A1 (en) 2020-11-13 2024-01-11 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34277A (en) * 1862-01-28 Improvement in lamps
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.

Also Published As

Publication number Publication date
HUT72616A (en) 1996-05-28
AU5114893A (en) 1994-04-26
JP3064419B2 (ja) 2000-07-12
JPH08501787A (ja) 1996-02-27
TW372234B (en) 1999-10-21
NO313141B1 (no) 2002-08-19
FI951593A (fi) 1995-04-04
ES2096328T3 (es) 1997-03-01
NO951200D0 (no) 1995-03-29
US5977375A (en) 1999-11-02
ATE147734T1 (de) 1997-02-15
HU225973B1 (en) 2008-02-28
ZA937316B (en) 1994-04-22
KR950703545A (ko) 1995-09-20
SK43895A3 (en) 1995-08-09
GR3022286T3 (en) 1997-04-30
FR2696464A1 (fr) 1994-04-08
FR2696464B1 (fr) 1994-11-10
WO1994007876A1 (fr) 1994-04-14
RU2123493C1 (ru) 1998-12-20
CA2146372C (fr) 2003-09-09
DE69307526D1 (de) 1997-02-27
EP0663905A1 (fr) 1995-07-26
KR100290663B1 (ko) 2001-09-17
CZ284818B6 (cs) 1999-03-17
SK281035B6 (sk) 2000-11-07
FI115909B (fi) 2005-08-15
CZ83995A3 (en) 1995-09-13
US5717103A (en) 1998-02-10
PL308239A1 (en) 1995-07-24
EP0663905B1 (fr) 1997-01-15
PL178090B1 (pl) 2000-02-29
FI951593A0 (fi) 1995-04-04
HU9500970D0 (en) 1995-06-28
NZ256443A (en) 1996-07-26
NO951200L (no) 1995-03-29
RU95110766A (ru) 1996-12-27
AU689446B2 (en) 1998-04-02
CA2146372A1 (fr) 1994-04-14
MX9305764A (es) 1995-01-31
DE69307526T2 (de) 1997-05-22

Similar Documents

Publication Publication Date Title
DK0663905T3 (da) Ny fremgangsmåde dtil forestring af baccatin III og 10-desacetylbaccatin III
DK0663906T3 (da) Fremgangsmåde til fremstilling af taxanderivater
FI951592A0 (fi) Menetelmä taksaanijohdannaisten valmistamiseksi
DK0663907T3 (da) Fremgangsmåde til fremstilling af taxanderivater
FI943644A0 (fi) Uudet happoanhydridit, niiden valmistus ja käyttö